Management of Crohn’s disease from efficacy, quality of life and health economic perspectives

References

• Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology124(2), 521–536 (2003).
   PubMed Web of Science ®Google Scholar
• Ahmad T, Armuzzi A, Bunce M etal The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122 (4), 854–866 (2002).
   PubMed Web of Science ®Google Scholar
• Mourn B, Ekbom A, Vatn MH etal. Clinical course during the first year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990–1993. Scand.j GastroenteroL 32 (10), 1005–1012 (1997).
   Google Scholar
• Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population based study. Gastroenterology 121(2), 255–260 (2001).
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, Binder V Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35(3), 360–362 (1994).
   PubMed Web of Science ®Google Scholar
• ••First description of outcome aftercorticosteroid therapy and the basis of many pharrnacoeconomic modelling.
   Google Scholar
• Arnott IDR, Watts D, Ghosh S. Is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment PharmacoL Ther. 16(5), 857–867 (2002).
   Google Scholar
• Tibble JA, Sigthorson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology119(1), 15–22 (2000).
   PubMed Web of Science ®Google Scholar
• Casellas F, Lopez-Vivancos J, Casado A, Malagelada JR. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res. 11(8), 775–781 (2002).
   Google Scholar
• Konig HH, Ulshofer A, Gregor M etal. Validation of the EuroQ0L questionnaire in patients with inflammatory bowel disease. Euro GastroenteroL HepatoL 14(11), 1205–1215 (2002).
   Google Scholar
• Feagan BG. Economic issues in Crohn's disease — assessing the effects of new treatments on health-related quality of life. Aliment Pharm. Ther. 13\(Suppl. 4), 29–37 (1999).
   Google Scholar
• •Describes assessment of quality of life in the context of new therapies for Crohn's disease.
   Google Scholar
• Blomqvist P, Ekbom A. Inflammatory bowel diseases: healthcare and costs in Sweden in 1994. Scand. j Gastroenterol 32(11), 1134–1139 (1997).
   Google Scholar
• Hay AR. Hay JW. Inflammatory bowel disease: medical cost algorithms. Clin. GastroenteroL 14(4), 318–327 (1992).
   Google Scholar
• ••The basis of many laterpharrnacoeconomic studies.
   Google Scholar
• Hay JW. Hay AR. Inflammatory bowel disease: costs-of-illness. J. Clin. Gastroenterol 14(4), 309–317 (1992).
   Google Scholar
• ••first thorough study of the cost-of-illness in inflammatory bowel disease, showing the impact of hospitalization and surgery.
   Google Scholar
• Feagan BG, Vreeland MG, Larson LR et al Annual cost of care for Crohn's disease: A payor perspective. Am. J. GastroenteroL 95 (8), 1955-1960 (2000).
   Google Scholar
• Cohen RD, Larson LR, Roth JM etal The cost of hospitalization in Crohn's disease. Am. Gastroenterol 95(2), 524–530 (2000).
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Papineau N, Zajaczkowski J et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am. J. GastroenteroL 95(3), 677–683 (2000).
   Google Scholar
• Trallori G, Messori A. Drug treatments for maintaining remission in Crohn's disease. A lifetime cost—utility analysis. PharmacoEconomics 11,444–453 (1997).
   Google Scholar
• Blomqvist P, Feltelius N, Lofberg R, Ekbom A. A 10-year survey of inflammatory bowel diseases—drug therapy, costs and adverse reactions. Aliment Pharmacol Thec 15(4), 475–481 (2001).
   Google Scholar
• •Thorough long-term study of drugs used and associated costs in inflammatory bowel disease.
   Google Scholar
• Irvine EJ, Greenberg GR, Feagan BG etal Quality of life improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Inflamm. Bowel Dis. 6(3), 181–187 (2000).
   Google Scholar
• Van Dullemen HM, van Deventer SJH, Hommes DW et al Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology109(1), 129–135 (1995).
   Google Scholar
• Targan SR, Hanauer SB, van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-a for Crohn's disease. N EngL I Med. 337(15), 1029–1035 (1997).
   Google Scholar
• Present DH, Rutgeerts P, Targan S et al Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl. Med. 340(18), 1398–1405 (1999).
   Web of Science ®Google Scholar
• Rutgeerts P, D'Haens G, Targan A etal Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroentemlogy117(4), 761–769 (1999).
   PubMed Web of Science ®Google Scholar
• Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 117(2), 429–432 (1999).
   PubMed Web of Science ®Google Scholar
• Arnott IDR, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Phatmacol Ther. 15(10), 1639–1646 (2001).
   Google Scholar
• Ricart E, Panaccione R, Loftus E etal Infliximab for Crohn's disease in clinical practice at the mayo clinic. The first 100 patients. Ainj Gastroenterol 96(3), 722–729 (2001).
   Google Scholar
• Kugathasan S, Werlin S, Martinez A, Rivera MT, Heeikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am I Gastroenterol 95(11), 3189–3194 (2000).
   PubMed Web of Science ®Google Scholar
• Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ et al Use of infliximab in pediatric patients with inflammatory bowel disease. Ann. Pharmacother. 35(7-8), 823–828 (2001).
   PubMed Web of Science ®Google Scholar
• Nikolaus S, Raedler A, Kuhbacker T, Sfikas N, Folsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 356 (9240), 1475–1479 (2000).
   PubMed Web of Science ®Google Scholar
• National Institute of Clinical excellence (NICE). Guidance on the use of infliximab for Crohn's disease. Technology Appraisal Guidance 40, April (2002).
   Google Scholar
• Clark W, Raftery J, Song F, Barton P, Cummins C, Fry-Smith A. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technology Assess. 7(3), 1–78 (2003).
   PubMedGoogle Scholar
• •Systematic review of economic evaluation of infliximab.
   Google Scholar
• Feagan BG, Enns R, Fedorak RN eta]. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can. J. Gun. Pharmacol. 8(4), 188–198 (2001).
   Google Scholar
• Rubinstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J. Gun.Gastroenterol 35(2), 151–156 (2002).
   Google Scholar
• Mitton OR. Funding the new biologics — a health economic critique of the CCOHTA report — infliximab for the treatment of Crohn's disease. Can. J. Gastroenterol 16(12), 873–876 (2002).
   Google Scholar
• Baert F, Norman M, Vermiere S etal Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl. I Merl 348(7), 601–608 (2003).
   Google Scholar
• Farrell RJ, Alsahli M, Jeen Y, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124(4), 917–924 (2003).
   PubMed Web of Science ®Google Scholar
• Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and on demand therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am. Gastroenterol 98(3), 608–612 (2003).
   Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Stack WA, Mann SD, Roy AJ eta]. Randomized controlled trial of CDP571 antibody to tumour necrosis factor-a in Crohn's disease. Lancet 349(9051), 521–524 (1997).
   Google Scholar
• Sandborn WJ, Feagan BG, Hannuer SB et a/. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroentemlogy120, 1330–1338 (2001).
   Google Scholar
• Fedorak RN, Gangl A, Elson CO et al. Recombinant human interleukin 10 in the treatment of patients with mild-to-moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Co-operative Study Group. Gastroenterology 119 (6), 1473–1482 (2000).
   Google Scholar
• Colombel JF, Rutgeerts P, Malchow H et Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49(1), 42–46 (2001).
   Google Scholar
• Schreiber S, Fedorak RN, Nielsen OH etal Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Gastroenterology119(6), 1461–1472 (2000).
   Google Scholar
• Canva-Delcambre V, Jacquot S, Robinet E etal Treatment of severe Crohn's disease with antiCD4 monoclonal antibody. Aliment Pharmacol. Ther. 10(5), 721–727 (1996).
   Google Scholar
• Sands BE, Bank S, Sninsky CA et al Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology117 (1), 58–64 (1999).
   Google Scholar
• Schreiber S, Nikolaus S, Malchow H et al Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120(6), 1339–1346 (2001).
   Google Scholar
• Gordon FH, Lai CWY, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to a4 integrin in active Crohn's disease. Gastroenterology121 (2), 268–274 (2001).
   Google Scholar
• Ghosh S, Goldin E, Gordon FH etal Natalizumab for active Crohn's disease. N Engl. Merl 348(1), 24–32 (2003).
   Google Scholar
• Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm. Bowel Dis. 5(4), 239–245 (1999).
   Google Scholar
• Ferguson A, Glen M, Ghosh S. Crohn's disease: nutrition and nutritional therapy. Balliemi Clin. Gastroenterol. 12(1), 93–114 (1998).
   Google Scholar
• Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology108(4), 1056–1067 (1995).
   PubMed Web of Science ®Google Scholar
• Fernandez-Banares F, Cabre E, Esteve-Comas M, Gassul MA. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. J. Parenter. Enteral. Nutc 19(5), 356–364 (1995).
   Google Scholar
• Gui GP, Thomas PRS, Tizard MLV etal. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. j Antimicrob. Chemother. 39(3), 393–400 (1997).
   Google Scholar
• Thomas GAO, Swift GL, Green JT eta]. Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow-up study. Gut 42(4), 497–500 (1998).
   PubMed Web of Science ®Google Scholar
• Borgaonkar M, Macintosh D, Fardy J, Simms L. Antituberculous therapy for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev 2:CD000299 (2000).
   Google Scholar
• Weinstein TA, Sciubba JJ, Levine J. Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease. J. Perliatc Gastroenterol. Nutc 28(2), 214–216 (1999).
   Google Scholar
• Ehrenpreis ED, Kane SV, Cohen LB etal Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology117 (6), 1271–1277 (1999).
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Kam LY, Abreu-Martin MT etal An open-label pilot study of low-dose thalidomide in chronically active, steroid dependent Crohn's disease. Gastroenterology117(6), 1278–1287 (1999).
   PubMed Web of Science ®Google Scholar
• Hommes D, van den Blink B, Plasse T etal Inhibition of stress-activated MAPKs induces clinical improvement in moderate-to-severe Crohn's disease. Gastroenterology 122(1), 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• Neurath ME, Wanitschke R, Peters M etal Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 44(5), 625–628 (1999).
   PubMed Web of Science ®Google Scholar
• Miehsler W, Reinisch W Moser G etal Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am. .1. Gastmenterol 96 (3), 782–787 (2001).
   Google Scholar
• Casson DH, Eltumi M, Tomlin S etal. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 47(3), 436–440 (2000).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am. J: Gastmenterol. 92(5), 876–879 (1997).
   Google Scholar
• Ierardi E, Principi M, Francavilla R eta]. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther. 15(3), 371–377 (2001).
   PubMed Web of Science ®Google Scholar
• Belluzzi A, Brignola C, Campieri M eta]. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N. Engl. Med. 334(24), 1557–1560 (1996).
   Google Scholar
• Lorenz-Meyer H, Bauer P, Nicolay C etal Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Scam! j Gastmenterol 31(8), 778–785 (1996).
   Google Scholar
• Bodger K. Cost of illness of Crohn's disease. PharmacoEconomits 20 (10), 639–652 (2002).
   PubMed Web of Science ®Google Scholar